利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.032 秒)

    Meterodimeric T lymphocyte receptor antibody
    1.
    发明授权
    Meterodimeric T lymphocyte receptor antibody 失效
    甲基二聚体T淋巴细胞受体抗体

    公开(公告)号：US5189147A

    公开(公告)日：1993-02-23

    申请号：US271216

    申请日：1988-11-14

    申请人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    发明人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    IPC分类号： A61K39/00 ,  C07K14/725

    CPC分类号： C07K14/7051 ,  A61K39/00

    摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA cones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressedThe U.S. government has rights in this invention by virtue of Grant No. NIH-5-POl-CA28900-04, NIH-5-P30-CA14051-13 and the Arthritis Foundation.

    摘要翻译： 公开了包含α和β亚基的异二聚体T淋巴细胞受体。 每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。 两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。 使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA锥来确定淋巴细胞受体的结构，氨基酸和核苷酸序列。 与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。 蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

    Influenza Therapeutic
    2.
    发明申请
    Influenza Therapeutic 审中-公开
    流感治疗

    公开(公告)号：US20090124567A1

    公开(公告)日：2009-05-14

    申请号：US12167593

    申请日：2008-07-03

    申请人： Jianzhu Chen ,  Herman N. Eisen ,  Qing Ge

    发明人： Jianzhu Chen ,  Herman N. Eisen ,  Qing Ge

    IPC分类号： A61K31/7052 ,  C07H21/00 ,  C12N5/00 ,  A61P31/16 ,  C12N15/63 ,  A01K67/033

    CPC分类号： C12N15/1131 ,  A61K38/00 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/32 ,  C12N2799/021

    摘要： The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.

    摘要翻译： 本发明提供了用于基于RNA干扰（RNAi）现象抑制流感感染和/或复制的方法和组合物以及用于鉴定用于抑制流感病毒的有效siRNA和shRNA以及用于研究流感病毒感染机制的系统的系统。 本发明还提供用于抑制感染，致病性和/或其他感染因子的复制的方法和组合物，特别是感染可以从身体外部直接接近的细胞的感染，例如皮肤细胞或粘膜细胞的方法和组合物。 此外，本发明提供了包含RNAi诱导实体的组合物，例如靶向流感病毒转录物的siRNA，shRNA或RNAi诱导载体以及各种递送试剂中的任何一种。 本发明还包括使用该组合物治疗流感的方法。

    Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
    3.
    发明授权
    Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent 失效
    通过热休克蛋白融合蛋白诱导的体内CTL映射到离散的结构域，并且是CD4 + T细胞非依赖性的

    公开(公告)号：US07501125B2

    公开(公告)日：2009-03-10

    申请号：US10885523

    申请日：2004-07-01

    申请人： Qian Huang ,  Joan F. L. Richmond ,  Bryan K. Cho ,  Deborah Pallister ,  Jianzhu Chen ,  Herman N. Eisen ,  Richard A. Young

    发明人： Qian Huang ,  Joan F. L. Richmond ,  Bryan K. Cho ,  Deborah Pallister ,  Jianzhu Chen ,  Herman N. Eisen ,  Richard A. Young

    IPC分类号： A61K38/00 ,  A61K39/00 ,  A61K39/385 ,  C07K14/00 ,  C07K14/005 ,  C07K14/195

    CPC分类号： C07K14/35 ,  A61K39/00 ,  A61K47/62 ,  A61K47/6425 ,  A61K2039/57 ,  C07K2319/00

    摘要： The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.

    摘要翻译： 本发明涉及对CD4 + T细胞缺陷的个体中的分子诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到分子的hsp的hsp或一部分ATP结合结构域。 在一个实施方案中，本发明涉及在CD4 + T细胞缺乏的个体中治疗HIV的方法，其包括向所述个体施用连接到分子的hsp的一个或多个ATP结合结构域的一部分。 本发明还包括在个体中诱导CD4 +独立CTL应答的方法，其包括向所述个体施用连接到分子的hsp的ATP结合结构域的一部分。 本发明还涉及在个体中诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到该分子的hsp的ATP结合结构域的一部分。 此外，本发明涉及一种组合物，其特征在于与分子连接的hsp的ATP结合域的一部分。

    Heterodimeric T lymphocyte receptor subunit
    5.
    发明授权
    Heterodimeric T lymphocyte receptor subunit 失效
    异二聚体T淋巴细胞受体亚单位

    公开(公告)号：US5580961A

    公开(公告)日：1996-12-03

    申请号：US210326

    申请日：1994-03-18

    申请人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    发明人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    IPC分类号： C07K14/725 ,  C07K14/00

    CPC分类号： C07K14/7051

    摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor submit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.

    摘要翻译： 公开了异二聚体T淋巴细胞受体亚基。 亚基由可变，连接，恒定，跨膜和胞质区组成。 使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体递交的结构，氨基酸和核苷酸序列。 与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。 蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

    Heterodimeric T lymphocyte receptor
    6.
    发明授权
    Heterodimeric T lymphocyte receptor 失效
    异二聚体T淋巴细胞受体

    公开(公告)号：US4970296A

    公开(公告)日：1990-11-13

    申请号：US385897

    申请日：1989-07-27

    申请人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    发明人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/725

    CPC分类号： C07K14/7051 ,  A61K38/00 ,  A61K39/00

    摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.

    摘要翻译： 公开了包含α和β亚基的异二聚体T淋巴细胞受体。 每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。 两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。 使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的CDNA克隆测定淋巴细胞受体的结构，氨基酸和核苷酸序列。 与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。 蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

    System for delayed and pulsed release of biologically active substances
    7.
    发明授权
    System for delayed and pulsed release of biologically active substances 失效
    延迟和脉冲释放生物活性物质的系统

    公开(公告)号：US4921757A

    公开(公告)日：1990-05-01

    申请号：US92554

    申请日：1987-09-03

    申请人： Margaret A. Wheatley ,  Robert S. Langer ,  Herman N. Eisen

    发明人： Margaret A. Wheatley ,  Robert S. Langer ,  Herman N. Eisen

    IPC分类号： A61K9/127 ,  A61K9/50 ,  A61K9/70

    CPC分类号： A61K9/703 ,  A61K9/127 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/7084 ,  Y10S436/829 ,  Y10S514/963 ,  Y10S514/965 ,  Y10T428/2984

    摘要： A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the liposome is engineered by modifying the composition and method for making the liposomes, thereby producing liposomes which are sensitive to a specific stimuli such as temperature, pH, or light; or by including a phospholipase within some or all of the liposomes or the surrounding matrix; or by destabilizing the liposome to break down over a period of time; or by any combination of these features.

    摘要翻译： 公开了一种在一段时间内或以离散脉冲以恒定速率在体内和体外捕获的物质的系统。 诸如药物，激素，酶，遗传物质，包括病毒的抗原，疫苗或诸如染料和营养素的无机材料的生物活性物质被包埋在通过包封在半渗透性微胶囊内的生物环境中保护的脂质体中 可渗透聚合物基体。 被截留的物质释放到周围环境中由脂质体和周围基质对物质的渗透性决定。 通过改变制备脂质体的组合物和方法来改进脂质体的渗透性，从而产生对特定刺激如温度，pH或光敏感的脂质体; 或通过在一些或全部脂质体或周围基质中包含磷脂酶; 或通过不稳定脂质体在一段时间内分解; 或通过这些特征的任意组合。

    Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
    8.
    发明授权
    Production and use of monoclonal antibodies to phosphotyrosine-containing proteins 失效
    生产和使用含磷酸酪氨酸蛋白的单克隆抗体

    公开(公告)号：US4543439A

    公开(公告)日：1985-09-24

    申请号：US449355

    申请日：1982-12-13

    申请人： A. Raymond Frackelton, Jr. ,  Herman N. Eisen ,  Alonzo H. Ross

    发明人： A. Raymond Frackelton, Jr. ,  Herman N. Eisen ,  Alonzo H. Ross

    IPC分类号： C07K16/18 ,  G01N33/68 ,  C12N15/00 ,  G01N33/60

    CPC分类号： G01N33/6842 ,  C07K16/18 ,  G01N33/68 ,  Y10S435/948

    摘要： A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.

    摘要翻译： 公开了杂交瘤细胞系，其分泌用作生物/医学研究中用于分离和鉴定含磷酸酪氨酸的蛋白质的高滴度，可重复的生物试剂的单克隆抗体。 此外，该抗体在诊断各种疾病（包括某些癌症）中具有潜在的用途。 已经证实对含有o-磷酸酪氨酸残基的各种分子的亲和力的抗体是使用与载体蛋白共价连接的合成类似物对偶氮苄基膦酸酯（ABP）作为抗原制备的。

    Heterodimeric T lymphocyte receptor
    9.
    发明授权
    Heterodimeric T lymphocyte receptor 失效
    异二聚体T淋巴细胞受体

    公开(公告)号：US5882945A

    公开(公告)日：1999-03-16

    申请号：US262827

    申请日：1994-06-21

    申请人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    发明人： Haruo Saito ,  David M. Kranz ,  Herman N. Eisen ,  Susumu Tonegawa

    IPC分类号： A61K39/00 ,  C07K14/725 ,  G01N33/531 ,  C07K16/28

    CPC分类号： C07K14/7051 ,  A61K39/00

    摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.

    摘要翻译： 公开了异二聚体T淋巴细胞受体亚基。 亚基由信号肽，可变，连接，恒定，跨膜和细胞质区组成。 使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。 与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。 蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

    System for controlled release of biologically active compounds
    10.
    发明授权
    System for controlled release of biologically active compounds 失效
    用于控制释放生物活性化合物的系统

    公开(公告)号：US4933185A

    公开(公告)日：1990-06-12

    申请号：US223887

    申请日：1988-07-11

    申请人： Margaret A. Wheatley ,  Robert S. Langer ,  Herman N. Eisen

    发明人： Margaret A. Wheatley ,  Robert S. Langer ,  Herman N. Eisen

    IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K9/62

    CPC分类号： A61K9/1664 ,  A61K9/1652 ,  A61K9/5031 ,  Y10S514/885 ,  Y10S514/963 ,  Y10T428/2984 ,  Y10T428/2985

    摘要： A controlled release system for delivery of a biologically-active substance. In one embodiment, there is a delayed release of a biologically-active substance. In a second embodiment, the delayed release is preceded by an initial release of biologically active substance. In other variations of the system, there are mulitple discrete releases over time or a continuous slow release combined with discrete releases. The delayed exposure is achieved through the design and construction of the system, specifically, formation of ionically-coated microcapsules around the biologically-active substance in conjunction with a microcapsule core-degrading enzyme. Release of active substance takes place in a burst at such a time as the core degrading enzyme has reduced the core to a molecular weight too low to support enough interaction with the cationic skin to maintain its integrity as a skin. In one example, microcapsules are formed of an ionically cross-linked polysaccharide, calcium alginate, which is further ionically coated with a poly-cationic skin of poly-L-lysine. The capsule coating serves a dual purpose: to control diffusion of the biologically-active substance and the core-degrading enzyme and as a substrate for the mechanism by which the biologically-active substance is released after a time delay.

    摘要翻译： 用于递送生物活性物质的控制释放系统。 在一个实施方案中，存在生物活性物质的延迟释放。 在第二个实施方案中，延迟释放之前是生物活性物质的初始释放。 在系统的其他变体中，随着时间的推移有多种离散的释放，或者连续的缓慢释放与离散的释放相结合。 延迟曝光是通过系统的设计和构建来实现的，具体地说，在微生物活性物质周围与微胶囊核心降解酶结合形成离子涂覆的微胶囊。 活性物质的释放在核心降解酶已经将核心降低到分子量太低以至于不能支持与阳离子皮肤的足够相互作用以维持其作为皮肤的完整性的时候发生。 在一个实例中，微胶囊由离子交联的多糖，藻酸钙形成，其进一步离子地涂覆有聚-L-赖氨酸的多阳离子皮肤。 胶囊涂层具有双重目的：控制生物活性物质和核心降解酶的扩散，并且作为延迟后释放生物活性物质的机制的底物。